ArticleJournal for immunotherapy of cancer2022

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.

Ana Oaknin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.